Literature DB >> 27354594

Impact of Genetic Variation in MicroRNA-binding Site on Susceptibility to Colorectal Cancer.

Byung Woog Kang1, Hyo-Sung Jeon2, Yee Soo Chae1, Soo Jung Lee1, Jun Seok Park3, Gyu Seog Choi3, Jong Gwang Kim4.   

Abstract

The present study analyzed single nucleotide polymorphisms (SNPs) located at putative microRNA(miRNA)-binding sites of the 3'-untranslated region (UTR) in different genes and investigated their impact on the susceptibility to colorectal cancer (CRC). Ninety-two SNPs were selected using an in silico analysis of 3'-UTR SNPs in an SNP database and their miRNA binding efficiency was calculated using several miRNA databases and the HapMap database. Two independent study sets were used: 380 healthy controls and 371 patients with colorectal adenocarcinoma for the discovery set, and 521 healthy controls and 524 patients with colorectal adenocarcinoma for the validation set. The SNP genotyping was performed using a Sequenom MassARRAY. In addition, a luciferase assay was used to investigate whether miR-370 modulated docking protein 3 (DOK3) gene expression when rs2279398G>A was included in the DOK3 3'-UTR region. For the discovery set, 16 out of 92 SNPs were significantly associated with the risk of CRC in at least one of the genetic models. The validation set showed that among these 16 SNPs, DOK3 rs2279398G>A was significantly associated with reduced risk of CRC in a recessive model [adjusted odds ratio (aOR)=0.65, 95% confidence interval (CI)=0.44-0.97, p=0.03]. In a combined analysis, DOK3 rs2279398G>A was associated with a significantly reduced risk of CRC in a co-dominant and recessive model (aOR=0.84, 95% CI=0.73-0.96, p=0.012; aOR=0.65, CI=0.49-0.88, p=0.004, respectively). Significantly lower Renilla activity was also observed with the rs2279398 AA construct when compared to the rs2279398 GG construct (p<0.001). DOK3 rs2279398G>A may affect the expression of DOK3 by altering the miRNA binding efficiency at the miRNA-binding sites of the 3'-UTR in DOK3, thereby impacting CRC tumorigenesis. Copyright
© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Colorectal cancer; DOK3; microRNA target gene; polymorphism; susceptibility

Mesh:

Substances:

Year:  2016        PMID: 27354594

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

Review 1.  Colorectal Cancer: From the Genetic Model to Posttranscriptional Regulation by Noncoding RNAs.

Authors:  María Antonia Lizarbe; Jorge Calle-Espinosa; Eva Fernández-Lizarbe; Sara Fernández-Lizarbe; Miguel Ángel Robles; Nieves Olmo; Javier Turnay
Journal:  Biomed Res Int       Date:  2017-05-10       Impact factor: 3.411

2.  MicroRNAs in Genetic Etiology of Human Diseases.

Authors:  Melis Olcum; Kemal Ugur Tufekci; Sermin Genc
Journal:  Methods Mol Biol       Date:  2022

3.  MicroRNA-binding site polymorphisms and risk of colorectal cancer: A systematic review and meta-analysis.

Authors:  Morteza Gholami; Bagher Larijani; Farshad Sharifi; Shirin Hasani-Ranjbar; Reza Taslimi; Milad Bastami; Rasha Atlasi; Mahsa M Amoli
Journal:  Cancer Med       Date:  2019-10-21       Impact factor: 4.452

Review 4.  Preeclampsia, Natural History, Genes, and miRNAs Associated with the Syndrome.

Authors:  Laura Parada-Niño; Luisa Fernanda Castillo-León; Adrien Morel
Journal:  J Pregnancy       Date:  2022-02-14

5.  Integrated analysis of mRNA-single nucleotide polymorphism-microRNA interaction network to identify biomarkers associated with prostate cancer.

Authors:  Zhiwen Wang; Xi Zhu; Hongyun Zhai; Yanghai Wang; Gangyue Hao
Journal:  Front Genet       Date:  2022-07-25       Impact factor: 4.772

6.  Associations of Functional MicroRNA Binding Site Polymorphisms in IL23/Th17 Inflammatory Pathway Genes with Gastric Cancer Risk.

Authors:  Kaiyan Dong; Yajuan Xu; Qian Yang; Jiachen Shi; Jicheng Jiang; Yi Chen; Chunhua Song; Kaijuan Wang
Journal:  Mediators Inflamm       Date:  2017-10-08       Impact factor: 4.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.